Drug intelligence / Profile preview

CR-101

Development stage: Unknown
Lead developer: Currax Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CR-101 is a small molecule drug candidate currently in Phase 1 clinical development by Currax Pharmaceuticals. The program is primarily focused on weight management. While the indication 'Shoulder Weight Gain' appears in some extracted pipeline documents, this is widely considered a transcription or OCR error for 'Smoking Cessation Weight Gain' or a similar metabolic condition, given the sponsor's therapeutic focus on obesity and CNS disorders. Currax Pharmaceuticals, which manages the established weight-loss combination Contrave (naltrexone/bupropion), is positioning CR-101 as a next-generation asset within its specialty pipeline, potentially utilizing novel formulations or delivery systems to improve outcomes in weight control.

Other names: CR-101CR101CR 101

Beyond the preview

Go deeper on CR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-101.

Explore the full profile